We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Brentuximab vedotin and anti-PD1 treatment optimize survival in chemo-refractory Hodgkin lymphoma patients: Real-world data.
- Authors
Sakellari, Ioanna; Gavriilaki, Eleni; Iskas, Michail; Bousiou, Zoi; Chatziioannidis, Aristotelis; Batsis, I.; Mallouri, Despina; Constantinous, Varnavas; Stavroyianni, Niki; Syrigou, Antonia; Marvaki, Anastasia; Pilavaki, Maria; Papaemmanouel, Styliani; Anagnostopoulos, Achilles
- Abstract
Brentuximab vedotin and anti-PD1 treatment optimize survival in chemo-refractory Hodgkin lymphoma patients: Real-world data Brentuximab vedotin (BV) and anti-PD1 treatment have been assigned to chemo-refractory Hodgkin lymphoma treatment.[[1]] Impact of these agents on overall survival (OS) after autologous hematopoietic cell transplantation (AHCT) remains under investigation. GLO:O85/01oct19:hon2645-fig-0002.jpg PHOTO (COLOR): 2 Significantly increased overall survival (p = 0.044) in patients receiving BV and anti-PD1 treatment (BV plus anti-PD1, black line), compared to patients receiving only BV (dotted black line) and historical controls (dotted grey line).
- Subjects
HODGKIN'S disease; BUSULFAN; HEPATIC veno-occlusive disease; MELPHALAN; HEMATOPOIETIC stem cells
- Publication
Hematological Oncology, 2019, Vol 37, Issue 4, p490
- ISSN
0278-0232
- Publication type
clinical trial
- DOI
10.1002/hon.2645